Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).

Grzegorz S. Nowakowski,Annalisa Chiappella,Thomas Elmer Witzig,Michele Spina,Randy D. Gascoyne,Lei Zhang,Jocelyne Flament,Jacqueline Repici,Erin Conlin,Krista Delissio,Umberto Vitolo

Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).

2016

Grzegorz S. Nowakowski
Annalisa Chiappella
Thomas Elmer Witzig
Michele Spina
Randy D. Gascoyne
Lei Zhang
Jocelyne Flament
Jacqueline Repici
Erin Conlin
Krista Delissio
Umberto Vitolo

7538Background: Gene expression profiling (GEP) represents a gold standard in identifying patients (pts) with activated B-cell–like (ABC) DLBCL, a subtype associated with inferior outcomes. Until r...

Keywords:

Gene expression
Diffuse large B-cell lymphoma
Lenalidomide
Placebo
Cancer research
CHOP
Pathology
Medicine
Oncology
in patient
Internal medicine
Gene expression profiling
Cell of origin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations